Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

-on therapy to a sulfonylurea when the single agent alone does not provide adequate glycemic control and as add-on therapy to the combination of a sulfonylurea plus metformin when dual therapy does not provide adequate glycemic control. The FDA is reviewing the sNDA for these indications and Merck expects FDA action by mid-October.

A pooled analysis of 5,141 patients showed overall incidence of adverse experiences, incidence of serious adverse experiences, and incidence of discontinuations due to adverse experiences were similar in the JANUVIA and non-exposed groups for up to two years (Poster #534-P)

The safety and tolerability of JANUVIA was assessed by pooling data from nine completed Phase IIB and III studies, including the studies discussed above, ranging from 24 to 104 weeks in duration, and including 5,141 patients treated with either JANUVIA 100 mg daily (n=2,786) or other treatments (placebo or an active comparator) (n=2,355). The studies assessed JANUVIA as monotherapy, initial combination therapy with metformin, or add-on to another oral agent (metformin, pioglitazone, sulfonylurea, or sulfonylurea and metformin).

JANUVIA 100 mg daily was generally well-tolerated as monotherapy, as initial combination therapy, or as add-on therapy. For adverse experiences (either clinical or laboratory), the overall incidence of adverse experiences, the incidence of serious adverse experiences, and the incidence of discontinuations due to adverse experiences were similar in the JANUVIA treated patients and in patients who received other therapies (patients on placebo or active comparator). Drug-related adverse experiences were higher in the non-exposed group due to hypoglycemia reported in sulfonylurea-treated patients (since studies in which a sulfonylurea agent was a treatment in patients not receiving JANUVIA were included in this pooled analysis).

Specific clinical adverse experiences, expressed as a rate of greater than or equal to 1 event
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
(Date:1/14/2014)...   Evidera , a leading provider of evidence-based solutions ... Drug Evaluation and Research (CDER), U.S. Food and Drug ... for a patient-reported outcome (PRO) measure in drug development: ... [EXACT] for Measurement of Symptoms of Acute Bacterial Exacerbation ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... A new study has found that India,s shocking rates ... debt-ridden farmers who are clinging to tiny smallholdings ... ,cash crops, such as cotton and coffee, that are ... supports a range of previous case studies that point ... sector following the ,liberalisation, of the nation,s economy during ...
(Date:4/17/2014)... the leading weapon against the deadly disease could be ... indicating it simply needs to be administered differently. , ... anti-malarial drug chloroquine in treating and preventing the mosquito-bourne ... a million people each year around the world. , ... chloroquine, but research carried out at the Australian National ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that final ... solid tumors, including long-term patient follow-up, have been published ... 232). The data demonstrate robust antibody and T cell ... very advanced cancers and suggest that CDX-1401 may predispose ...
Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... ... in Italy, in conjunction with a team of doctors from the ... confirming that Pecorino Romano Cheese contains high amounts of CLA (Conjugated ... food groups. The study reveals that even in small amounts, ...
... Yummy commercial food smells contain noxious gases, researchers say ... aromas that restaurants emit are actually a type of ... health and the environment, U.S. researchers report. , Gases ... out by commercial food cooking, according to Deborah Gross, ...
... ... for your interview. One Portland, Oregon business is providing support—literally—for today’s job seekers. ... (PRWEB) March 24, ... ), today announced a special discount offer for those seeking employment and looking for ...
... ... a healthcare consulting firm, launches new corporate website with enhanced content, navigation and performance. ... ... consulting services for the healthcare industry, is pleased to announce that it has launched ...
... ... and with celebrity appeal, generating success in a difficult economy. , ... (PRWEB) March 24, 2010 -- The ... celebrities., , ,Leeza Gibbons, popular entertainment personality and National Spokesperson for ZERONA, has proven ...
... ... asks that you join in recognizing all physicians on National Doctor,s Day, March 30 -- ... ... March 30 is National Doctor’s Day. The American Board of Physician Specialties (ABPS) ...
Cached Medicine News:Health News:Say Cheese! New Study Confirms Health Benefits of Pecorino Romano Cheese 2Health News:What's Cookin'? It Could Be Air Pollution 2Health News:Your Posture Can Make or Break Your Job Interview; PostureNOW Offers 33% Off Its Posture Corrective Brace to Job Seekers Nationwide 2Health News:Leading Healthcare Human Resource Consulting Firm, Integrated Healthcare Strategies, Launches New Website 2Health News:Leading Healthcare Human Resource Consulting Firm, Integrated Healthcare Strategies, Launches New Website 3Health News:Leeza Gibbons and ZERONA Equals a Winning Combination 2Health News:American Board of Physician Specialties (ABPS) Celebrates Doctor's Day 2010 2
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Surgical Stainless Steel Child Stylette....
Surgical Stainless Steel Adult 16.5....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
Medicine Products: